Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)-HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy

Video Transcription

Video Summary

Summary:<br /><br />The video is a Heart Failure Society of America Heart Failure Seminar focused on hypertrophic cardiomyopathy (HCM). It discusses the genetics, pathophysiology, and diagnosis of HCM, as well as current and emerging treatment options. It highlights the use of cardiac myosin inhibitors as precision therapies for obstructive HCM, which have shown to improve symptoms and reduce left ventricular outflow tract obstruction. The seminar also mentions emerging therapies like gene replacement and editing therapy. Challenges in delivering gene therapy safely and selecting appropriate patients are noted. Overall, the seminar provides an overview of the current understanding and treatment options for HCM.<br /><br />Additionally, a case of a 48-year-old man with HCM and reduced ejection fraction is presented. The patient had a history of hypertension and presented with progressive shortness of breath. Initial evaluation confirmed the diagnosis of HCM and revealed scar tissue. Management involved stopping negative inotropic therapy, starting guideline-directed medical therapy, considering a defibrillator and cardiac resynchronization therapy, and referring the patient to smoking cessation counseling. The case emphasizes the importance of accurate diagnosis and personalized management for patients with HCM and reduced EF, considering clinical presentation, genotype, and scar tissue presence.<br /><br />Credits: The video is a Heart Failure Society of America Heart Failure Seminar.

Keywords

Hypertrophic Cardiomyopathy

Genetics

Diagnosis

Treatment options

Cardiac myosin inhibitors

Left ventricular outflow tract obstruction

Gene replacement therapy

Gene editing therapy

Reduced ejection fraction

Scar tissue

Guideline-directed medical therapy

Defibrillator

Personalized management